Skip to main content
Sister Publication Links
  • ESG: THE NEW IMPERATIVE
Subscribe
  • My Account
  • Login
  • Subscribe
  • News
    • Current News
    • COVID-19
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Transformation
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Digital Health
  • Insights
    • ACA 10 Years After
    • Best Practices
    • Special Reports
    • Innovations
  • Data/Lists
    • Rankings/Lists
    • Interactive Databases
    • Data Points
  • Op-Ed
    • Bold Moves
    • Breaking Bias
    • Commentaries
    • Letters
    • Vital Signs Blog
    • From the Editor
  • Awards
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top 25 Innovators
    • Diversity in Healthcare
    • Women in Healthcare
    • - Luminaries
    • - Top 25 Diversity Leaders
    • - Leaders to Watch
    • - Luminaries
    • - Top 25 Women Leaders
    • - Women to Watch
  • Events
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Custom Media Event: ESG Summit
    • Transformation Summit
    • Women Leaders in Healthcare Conference
    • Social Determinants of Health Symposium
    • Leadership Symposium
    • Health Care Hall of Fame Gala
    • Top 25 Women Leaders Gala
    • Best Places to Work Awards Gala
    • Top 25 Diversity Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Supply Chain Revenue Cycle
    • - Hospital at Home
    • - Workplace of the Future
    • - Strategic Marketing
    • - Virtual Health
  • Listen
    • Podcast - Next Up
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Video Series - The Check Up
    • Sponsored Video Series - One on One
  • MORE +
    • Advertise
    • Media Kit
    • Newsletters
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Finance
June 22, 2017 01:00 AM

Mylan shareholders re-elect board, reject executive compensation proposals

Alex Kacik
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    Shareholders of the embattled drugmaker Mylan voted to re-elect its board members at their annual shareholder meeting Thursday morning, despite pressure to oust select executives amid public and regulatory backlash for the skyrocketing price of EpiPens. Shareholders also rejected proposed executive pay packages at the meeting.

    Mylan executives had been under fire since the company drastically raised the price of EpiPens, epinephrine auto-injectors that are used in emergencies to stop severe allergy attacks, which had been sold in a two-pack for around $100 for years. The drug now tops $600, an increase of more than 500% since 2007, when Canonsburg, Pa.-based Mylan bought rights to the drug.

    Former CEO and current Mylan Chairman Robert Coury received a $98 million compensation package in 2016, and he and other top executives would have received bonuses under the executive pay proposals if the stock price hit certain benchmarks by the end of next year. The company used lofty price hikes and other strategies to reach those goals. Coury also stood to benefit from a $44 million equity grant that would've essentially guaranteed a hefty salary over the next five years.

    Institutional investment funds including the California State Teachers' Retirement System and the New York City and New York State comptrollers signed a letter to shareholders urging them to hold Mylan executives accountable "for a costly record of compensation, risk and compliance failures" and turn down executive packages. Critics questioned the value of Coury's role since he stepped down as CEO in 2012.

    "Last year was a new low for the Mylan board," the letter reads. "At its core, the EpiPen price-hiking controversy was the costly consequence of a board with a history of oversight failures. From allegedly overcharging both the government and consumers for its lifesaving EpiPen to approving exorbitant pay for its deeply entrenched chairman, Mylan's board has repeatedly enabled self-serving executives at shareowners' expense."

    Shareholders suffered a 29.4% loss in 2016, the letter said.

    Mylan, which has a stronghold on the auto-injector market, sparked a public outcry after it drastically raised the price of EpiPens, spawning congressional hearings and several lawsuits. The company faces a federal investigation for possible antitrust violations and class-action lawsuits over EpiPens throughout the country.

    One of the lawsuits came from its rival Sanofi, alleging Mylan's agreements with pharmacy benefit managers amount to illegal kickbacks. The plaintiffs claim that Mylan paid PBMs—including Express Scripts, CVS Health and OptumRx—to promote EpiPen over competitor allergy injectors, and those payments artificially increased prices. Mylan's actions violate federal racketeering law and state consumer protection laws for allegedly raising EpiPen's list price to provide kickbacks to PBMs, according to the lawsuit.

    Mylan reached a $465 million settlement with the federal government in September to settle allegations that it overbilled Medicaid. Yet, HHS' Office of Inspector General recently accused Mylan of overcharging federal taxpayers nearly $1.3 billion. It incorrectly classified the auto-injectors as generics, which means it paid Medicaid a 13% rebate instead of a 23% rebate, according to the government watchdog.

    U.S. Food and Drug Administration Commissioner Dr. Scott Gottlieb announced Wednesday that the agency is working on a Drug Competition Action Plan that aims to lower drug prices by getting more generic drugs to market sooner. The FDA looks to close regulatory loopholes that branded drugs use to thwart the development of generics.

    "We know that sometimes our regulatory rules might be 'gamed' in ways that may delay generic drug approvals beyond the time frame the law intended, in order to reduce competition," Gottlieb said in a statement. "We are actively looking at ways our rules are being used and, in some cases, misused."

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    Copy of finance_arrows_down_WEB_i_i_i.jpg
    Cleveland Clinic records Q1 operating loss as labor costs rise, admissions lag
    real cost of health care_i.png
    Betting on ‘Golden Age’ of colonoscopies, private equity invests in gastro docs
    Sponsored Content
    Daily Finance Newsletter: Sign up to receive daily news and data that has a direct impact on the business and financing of healthcare.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Advertise with Us
    • Ad Choices Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2022. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • COVID-19
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Digital Health
    • Insights
      • ACA 10 Years After
      • Best Practices
      • Special Reports
      • Innovations
    • Data/Lists
      • Rankings/Lists
      • Interactive Databases
      • Data Points
    • Op-Ed
      • Bold Moves
      • Breaking Bias
      • Commentaries
      • Letters
      • Vital Signs Blog
      • From the Editor
    • Awards
      • Nominate/Eligibility
      • 100 Most Influential People
      • 50 Most Influential Clinical Executives
      • Best Places to Work in Healthcare
      • Excellence in Governance
      • Health Care Hall of Fame
      • Healthcare Marketing Impact Awards
      • Top 25 Emerging Leaders
      • Top 25 Innovators
      • Diversity in Healthcare
        • - Luminaries
        • - Top 25 Diversity Leaders
        • - Leaders to Watch
      • Women in Healthcare
        • - Luminaries
        • - Top 25 Women Leaders
        • - Women to Watch
    • Events
      • Conferences
        • Transformation Summit
        • Women Leaders in Healthcare Conference
        • Social Determinants of Health Symposium
        • Leadership Symposium
      • Galas
        • Health Care Hall of Fame Gala
        • Top 25 Women Leaders Gala
        • Best Places to Work Awards Gala
        • Top 25 Diversity Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Supply Chain Revenue Cycle
        • - Hospital at Home
        • - Workplace of the Future
        • - Strategic Marketing
        • - Virtual Health
      • Webinars
      • Custom Media Event: ESG Summit
    • Listen
      • Podcast - Next Up
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Video Series - The Check Up
      • Sponsored Video Series - One on One
    • MORE +
      • Advertise
      • Media Kit
      • Newsletters
      • Jobs
      • People on the Move
      • Reprints & Licensing